These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 2529829)
1. [Prospective perimenopausal estrogen-progestin substitution therapies for the prevention of osteoporosis]. Dören M; Montag M; Schneider HP Arch Gynecol Obstet; 1989; 245(1-4):963-4. PubMed ID: 2529829 [No Abstract] [Full Text] [Related]
2. Does postmenopausal bone loss respond to estrogen replacement therapy independent of bone loss rate? Christiansen C; Rødbro P Calcif Tissue Int; 1983 Sep; 35(6):720-2. PubMed ID: 6652546 [TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters. Haiba NA; el-Habashy MA; Said SA; Darwish EA; Abdel-Sayed WS; Nayel SE Contraception; 1989 Jun; 39(6):619-32. PubMed ID: 2666019 [TBL] [Abstract][Full Text] [Related]
4. A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement. Williams SR; Frenchek B; Speroff T; Speroff L Am J Obstet Gynecol; 1990 Feb; 162(2):438-46. PubMed ID: 2309827 [TBL] [Abstract][Full Text] [Related]
5. Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate. Klehr-Bathmann I; Kuhl H Maturitas; 1995 Apr; 21(3):245-50. PubMed ID: 7616874 [TBL] [Abstract][Full Text] [Related]
6. A randomized, single blind comparative trial of norethindrone enanthate and depo-medroxyprogesterone acetate in Bangladesh. Swenson I; Khan AR; Jahan FA Contraception; 1980 Mar; 21(3):207-15. PubMed ID: 6446442 [TBL] [Abstract][Full Text] [Related]
7. [Dihydrogesterone vs. medroxyprogesterone acetate in association with transdermal estradiol in postmenopausal substitution treatment]. Delzanno G; Paoletti R; Gaudiano L; Bertinetti G; Ventrella CA; Dell'Elce C Minerva Ginecol; 1994 Apr; 46(4):179-82. PubMed ID: 8065591 [TBL] [Abstract][Full Text] [Related]
9. Long-term compliance of continuous combined estrogen and progestogen replacement in postmenopausal women. Dören M; Schneider HP Maturitas; 1996 Oct; 25(2):99-105. PubMed ID: 8905600 [TBL] [Abstract][Full Text] [Related]
10. Mammographic density changes during different postmenopausal hormone replacement therapies. Sendağ F; Coşan Terek M; Ozşener S; Oztekin K; Bilgin O; Bilgen I; Memiş A Fertil Steril; 2001 Sep; 76(3):445-50. PubMed ID: 11532462 [TBL] [Abstract][Full Text] [Related]
11. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201 [TBL] [Abstract][Full Text] [Related]
12. Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17beta-estradiol and norethindrone acetate. Odmark IS; Jonsson B; Bäckström T Am J Obstet Gynecol; 2001 May; 184(6):1131-8. PubMed ID: 11349178 [TBL] [Abstract][Full Text] [Related]
13. Effective bleeding control and symptom relief by lower dose regimens of continuous combined hormone replacement therapy: a randomized comparative dose-ranging study. Bruhat M; Rudolf K; Vaheri R; Kainulainen P; Timonen U; Viitanen A Maturitas; 2001 Dec; 40(3):259-71. PubMed ID: 11731187 [TBL] [Abstract][Full Text] [Related]